For the second quarter of 2026, analysts expect Imunon Inc to report zero revenue and a consensus loss per share of $0.94, while the stock currently trades at $1.59 relative to a bullish $17.00 average analyst price target.
The primary focus for investors is the enrollment momentum and safety profile of the pivotal Phase 3 OVATION 3 trial for advanced ovarian cancer treatment. Management’s update follows a June 2026 capital raise of $10 million aimed at supporting clinical advancement through late 2027. Investors are also seeking further long-term survival data from the completed Phase 2 OVATION 2 study to validate the immunotherapy's therapeutic potential ahead of a potential BLA filing.